56. Future Therapies of Osteoporosis

  1. Clifford J. Rosen MD
  1. Kong Wah Ng and
  2. T. John Martin

Published Online: 19 JUL 2013

DOI: 10.1002/9781118453926.ch56

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition

How to Cite

Ng, K. W. and Martin, T. J. (2013) Future Therapies of Osteoporosis, in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition (ed C. J. Rosen), John Wiley & Sons, Inc., Ames, USA. doi: 10.1002/9781118453926.ch56

Publication History

  1. Published Online: 19 JUL 2013

ISBN Information

Print ISBN: 9781118453889

Online ISBN: 9781118453926

SEARCH

Keywords:

  • anabolic agents;
  • antiresorptive agents;
  • osteoporosis

Summary

Insights into the mechanisms that govern the formation and function of osteoblasts and osteoclasts and their communication processes have led to specific points of intervention that are guiding the development of current and next generation therapies for osteoporosis. This chapter discusses several candidate molecules that have been identified with the potential to act as antiresorptive or anabolic agents. Preliminary results of studies with some of these molecules hold the promise that at least some of these new therapies may develop into effective means of treating and preventing osteoporosis. Initial drug development attempts in osteoporosis use monoclonal anti-DKK-1 reagents, but the possibility of directing small molecules to prevent the DKK-1-LRP5 interaction is being explored. The approach of targeting specific peptides that are known to play important roles in osteoblast formation or osteoclast action have yielded several promising candidates with the potential to become effective antiresorptive or anabolic agents to treat osteoporosis.